Research programme: influenza A virus H1N1 vaccine - Takeda

Drug Profile

Research programme: influenza A virus H1N1 vaccine - Takeda

Alternative Names: Vaccines against new forms of influenza - Takeda

Latest Information Update: 23 Jul 2014

Price : $50

At a glance

  • Originator Inviragen
  • Developer Takeda Pharmaceuticals USA
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 23 Jul 2014 No development reported - Preclinical for Influenza-A virus H1N1 subtype in USA (Parenteral)
  • 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
  • 27 Jan 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top